New independent market research shows that 84% of healthcare professionals will likely use Orviglance® for magnetic resonance imaging (MRI) in patients with cancer in the liver and reduced kidney function. The research confirms the clear unmet need for an effective alternative to unenhanced MRI and a safe alternative to gadolinium contrast agents.
Download the full presentation below
